CINECA IRIS Institutional Research Information System

MARTINELLI, ADRIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.412
AS - Asia 8.849
EU - Europa 6.847
SA - Sud America 1.163
AF - Africa 309
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 8
Totale 35.600
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.866
CN - Cina 2.966
SG - Singapore 2.434
IT - Italia 2.164
HK - Hong Kong 1.187
SE - Svezia 1.150
BR - Brasile 974
DE - Germania 833
VN - Vietnam 619
BG - Bulgaria 590
TR - Turchia 520
CA - Canada 445
GB - Regno Unito 392
FR - Francia 388
FI - Finlandia 312
UA - Ucraina 305
RU - Federazione Russa 280
KR - Corea 268
IN - India 252
JP - Giappone 138
CH - Svizzera 118
BD - Bangladesh 95
AT - Austria 70
BE - Belgio 60
AR - Argentina 54
IQ - Iraq 52
CI - Costa d'Avorio 51
PK - Pakistan 49
ZA - Sudafrica 45
MX - Messico 43
SN - Senegal 42
SA - Arabia Saudita 41
MA - Marocco 40
ID - Indonesia 39
UZ - Uzbekistan 39
ES - Italia 33
VE - Venezuela 33
NL - Olanda 32
EC - Ecuador 27
PL - Polonia 22
NG - Nigeria 21
CO - Colombia 20
EG - Egitto 20
KE - Kenya 20
GR - Grecia 19
IR - Iran 19
TN - Tunisia 19
JM - Giamaica 14
PY - Paraguay 14
CL - Cile 13
JO - Giordania 13
UY - Uruguay 13
IE - Irlanda 12
KZ - Kazakistan 12
NP - Nepal 12
IL - Israele 10
TT - Trinidad e Tobago 10
AE - Emirati Arabi Uniti 9
AU - Australia 9
DZ - Algeria 9
ET - Etiopia 9
PE - Perù 9
RO - Romania 9
DO - Repubblica Dominicana 8
PH - Filippine 8
AL - Albania 7
BY - Bielorussia 7
CR - Costa Rica 7
MY - Malesia 7
AZ - Azerbaigian 6
LB - Libano 6
AO - Angola 5
BJ - Benin 5
CZ - Repubblica Ceca 5
OM - Oman 5
PS - Palestinian Territory 5
PT - Portogallo 5
TW - Taiwan 5
BO - Bolivia 4
DK - Danimarca 4
GE - Georgia 4
KW - Kuwait 4
LT - Lituania 4
PA - Panama 4
TH - Thailandia 4
BA - Bosnia-Erzegovina 3
BB - Barbados 3
CY - Cipro 3
EU - Europa 3
HU - Ungheria 3
ML - Mali 3
NZ - Nuova Zelanda 3
RS - Serbia 3
SI - Slovenia 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
BH - Bahrain 2
BN - Brunei Darussalam 2
EE - Estonia 2
GA - Gabon 2
Totale 35.542
Salva come PNG Salva come JPEG
Città #
Woodbridge 2.270
Ann Arbor 2.075
Ashburn 1.608
Singapore 1.444
Houston 1.410
Fairfield 1.257
Hong Kong 1.172
Chandler 1.008
Santa Clara 803
San Jose 777
Serra 634
Milan 595
Sofia 588
Dallas 549
Seattle 527
Beijing 525
Chengdu 513
Shanghai 503
Wilmington 437
Jacksonville 394
Izmir 380
Cambridge 373
Ottawa 358
New York 344
Hefei 336
Seoul 258
Boardman 248
Princeton 241
Los Angeles 230
Lawrence 217
Nanjing 202
Lauterbourg 193
Medford 180
Dong Ket 163
Des Moines 142
Dearborn 118
Tokyo 116
Marseille 107
Bern 103
Ho Chi Minh City 102
Istanbul 97
Buffalo 90
The Dalles 90
Council Bluffs 89
Nanchang 88
Redondo Beach 88
Hanoi 86
Columbus 82
Florence 79
São Paulo 68
Boulder 66
San Diego 66
Jüchen 65
London 60
Redwood City 59
Helsinki 58
Vienna 55
Chicago 53
Munich 53
Rome 52
Abidjan 51
Brussels 47
Frankfurt am Main 43
Orem 43
Dakar 42
Kunming 40
Belo Horizonte 37
Nürnberg 37
Pune 37
Kansas City 36
Rio de Janeiro 36
Shenyang 35
Ogden 33
Tashkent 33
Dhaka 32
Pisa 32
Jiaxing 31
Changsha 30
Tianjin 30
Hebei 29
Guangzhou 28
Detroit 26
Jakarta 26
Norwalk 26
Baghdad 25
Falls Church 25
Hangzhou 25
San Francisco 25
Chennai 24
Turku 24
Bremen 23
Düsseldorf 23
Fuzhou 23
Casablanca 22
Phoenix 22
New Delhi 21
Toronto 20
Washington 20
Amsterdam 19
Lagos 19
Totale 26.144
Salva come PNG Salva come JPEG
Nome #
null 595
1,2,3-Triazolo[1,5-a][1,3]benzodiazepine a new heterocyclic system: Synthesis, benzodiazepine receptor binding and theoretical calculations 335
4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors 329
Chimica - VI Edizione Copyright © 2017, EdiSES srl - Napoli 314
Synthesis and 3D QSAR of New Pyrazolo[3,4-b]pyridines: Potent and Selective Inhibitors of A1 Adenosine Receptors 277
Phenylpropanoids and flavonoids from Phlomis kurdica as inhibitors of human lactate dehydrogenase. 265
Receptor-based virtual screening evaluation for the identification of estrogen receptor β ligands 260
THERMODYNAMIC PROPERTIES OF ORGANIC COMPOUNDS IN AQUEOUS-SOLUTIONS - APPARENT MOLAL HEAT-CAPACITIES OF AMINES AND ETHERS 251
1,2,3-triazolo[1.5-a]quinazolines: synthesis, benzodiazepine receptor binding and theoretical calculations 249
X-ray analisis, theoretical studies and a-adrenergic biopharmacological properties of 1-(2,5-dimethoxyphenyl)-2-aminoethanol and its morpholine analogue 238
Synthesis and biological evaluation of non-glucose glycoconjugated N-hydroyxindole class LDH inhibitors as anticancer agents 238
Identification of Lactate Dehydrogenase 5 Inhibitors using Pharmacophore- Driven Consensus Docking 234
Targeting Different Transthyretin Binding Sites with Unusual Natural Compounds 232
1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors. 230
CONFORMATIONAL STUDY OF ALPHA-BLOCKING ADRENERGIC-DRUGS WITH BENZODIOXANE STRUCTURE 225
X-Ray analysis, theoretical studies and alfa-adrenergic biopharmacological properties of 1-(2,5-dimethoxyphenyl)-2-aminoethanol and its morpholine analogue. 224
Reliability analysis and optimization of the consensus docking approach for the development of virtual screening studies 224
Development of terphenyl-2-methyloxazol-5(4H)-one derivatives as selective reversible MAGL inhibitors 220
A Virtual Screening Study for Lactate Dehydrogenase 5 Inhibitors by using a Pharmacophore-Based Approach 219
Structural optimization of 4-chlorobenzoylpiperidine derivatives for the development of potent, reversible and selective monoacylglycerol lipase (MAGL) inhibitors 219
MOLECULAR-ORBITAL STUDIES ON MECHANISM OF DRUG-RECEPTOR INTERACTION .2. BETA-ADRENERGIC DRUGS - APPROACH TO EXPLAIN ROLE OF AROMATIC MOIETY 217
N-ALKYL-NOR-TROPINE ESTERS OF 2-PHENYL-CYCLOHEXENIC ACIDS AS NEW BRONCHODILATOR AGENTS - EFFECT OF STRUCTURAL AND CONFORMATIONAL MODIFICATIONS ON AFFINITY FOR MUSCARINIC RECEPTORS 216
1,2-disubstituted cyclohexane derived tripeptide aldehydes as novel selective thrombin inhibitors 215
Discovery of 1,5-Diphenylpyrazole-3-Carboxamide Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors 215
Role of the acyloxymethyl moiety in eliciting the adrenergic ß-blocking activity of 3-acyloxypropanolamines 214
Rational Development of MAGL Inhibitors 210
Synthesis of Anthranylaldoxime Derivatives as Estrogen Receptor Ligands and Computational Prediction of Binding Modes 209
The [(Methyloxy)imino]methyl Moiety as a Bioisoster of Aryl. A Novel Class of Completely Aliphatic Beta-Adrenergic Receptor Antagonists 206
Identification of a new STAT3 dimerization inhibitor through a pharmacophore-based virtual screening approach 206
Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitors 206
Salicylaldoxime derivatives as new leads for the development of carbonic anhydrase inhibitors 203
Salicylaldoximes and anthranylaldoximes as alternatives to phenol-based estrogen receptor ligands 202
Synthesis of stable analogues of geranylgeranyl diphosphate possessing a (Z,E,E)-geranylgeranyl side chain, docking analysis, and biological assays for prenyl protein transferase inhibition 202
Salicylaldoximes and anthranylaldoximes as alternatives to phenol-based estrogen receptor ligands 201
Rational design, synthesis, biological evaluation and labelling of selective cannabinoid CB2 receptor agonists as anticancer agents 201
A CONFORMATIONAL APPROACH TO HISTAMINE H-2-RECEPTOR ANTAGONISTS 200
CONFORMATIONALLY RESTRAINED ANALOGS OF SYMPATHOMIMETIC CATECHOLAMINES - SYNTHESIS AND ADRENERGIC ACTIVITY OF TETRAHYDROBENZOCYCLOHEPTENE DERIVATIVES 200
Dual Targeting of the Warburg Effect with a Glucose-Conjugated Lactate Dehydrogenase Inhibitor 200
COMPOUNDS INHIBITING THE ENZYME LACTATE DEHYDROGENASE (LDH), PHARMACEUTICAL COMPOSITIONS AND USES THEREOF 200
Discovery of N-Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform a (LDH-A) as Starvation Agents against Cancer Cells 199
D3 dopamine receptor subtype: which binding modes for such different ligands?, 198
Synthesis and antimicrobial properties of substituted 3-aminoxy-(E)-2-methoxyiminopropionyl penicillins and cephalosporins 197
An overview of recent developments in GPCR modelling: methods and validation 197
Identification of new FYN kinase inhibitors using a FLAP-based approach 196
Antiproliferative oxime derivatives that inhibit glucose transporter 1 (GLUT1) in cancer cells 195
5-Amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a Versatile Scaffold to Obtain Potent and Selective A3 Adenosine Receptor Antagonists 194
Dual Inhibitors of Matrix Metalloproteinases and Carbonic Anhydrases: Iminodiacetyl-Based Hydroxamate-Benzenesulfonamide Conjugates 194
Selective inhibition of human erythrocyte Na+/K+ ATPase by cardiac glycosides and by a mammalian digitalis like factor 193
Design, Synthesis, Biological Evaluation, and NMR Studies of a New Series of Arylsulfones As Selective and Potent Matrix Metalloproteinase-12 Inhibitors 191
Computational studies of EGFR inhibitors: Docking, 3D-QSAR analysis and virtual screening evaluation 189
Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors 189
SYNTHESIS, ANTIINFLAMMATORY ACTIVITY AND MOLECULAR-ORBITAL STUDIES OF A SERIES OF BENZYLIDENEAMINOXYPROPIONIC ACIDS SUBSTITUTED ON THE PHENYL RING 188
N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity 188
Conformationally Restrained Analogs of Sympathomimetic Catecholamines. Synthesis, Conformational Analysis, and Adrenergic Activity of Isochroman Derivatives 188
D3 dopamine receptor subtype: which binding modes for such different ligands? 187
MOLECULAR DESIGN, SYNTHESIS, AND ANTIINFLAMMATORY ACTIVITY OF A SERIES OF BETA-AMINOXYPROPIONIC ACIDS 187
Conformationally restrained ß-blocking oxime ethers. 2. Synthesis and ß-adrenergic properties of diastereoisomeric anti and syn 2-(5’-(3’-aryl-substituted)isoxazolidinyl)-N-alkylethanolamines 186
Highly Selective Salicylketoxime-Based Estrogen Receptor β Agonists Display Antiproliferative Activities in a Glioma Model 186
Synthesis and ß-adrenergic properties of (E)-N-[3-(alkylamino)-2- hydroxypropilidene](methyloxy)amines substituted with an aromatic group on their [(methyloxy)imino]methyl moiety (MOIMM): an investigation into the biopharmacological effects of an aryl substitution in the class of MOIM ß-blocking drugs. 185
Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides 185
Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alfa- and beta-adrenergic receptors 184
Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximes 182
Olivetol- and Resorcinol-Anandamide “hybrids”: design, synthesis, binding and molecular modeling of potent cannabinoid receptor ligands 181
Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds 180
Design, Synthesis and biological evaluation of new 1,8-naphthyridin-4(1h)-on-3-carboxamide and quinolin-4(1h)-on-3-carboxamide derivatives as CB2 selective agonists 179
Cannabinoid CB2/CB1 Selectivity. Receptor Modeling and Automated Docking Analysis 179
Design of transthyretin amyloidosis inhibitors: A docking and virtual screening approach 179
N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation 179
2-(Methyleneaminoxy)methylmorpholine derivatives. Synthesis and antidepressant activity 178
N-O-Isopropyl Sulfonamido-Based Hydroxamates: Design, Synthesis and Biological Evaluation of Selective Matrix Metalloproteinase-13 Inhibitors as Potential Therapeutic Agents for Osteoarthritis 178
Development of a Fingerprint-Based Scoring Function for the Prediction of the Binding Mode of Carbonic Anhydrase II Inhibitors 178
Conformationally restrained β -blocking oxime ethers: synthesis and β -adrenergic properties of diastereoisomeric anti and syn 2-(5-isoxazolidinyl)ethanolamines 178
Selective activators of estrogen receptor beta based on the aldoxime and ketoxime scaffolds 177
Design, synthesis, binding, and molecular modeling studies of new potent ligands of cannabinoid receptors 175
Different Binding Modes of Structurally Diverse Ligands for Human D3DAR 175
An interdisciplinary approach to the design of new structures active at the beta-adrenergic receptor. Aliphatic oxime ether derivatives 175
Conformationally restrained analogues of sympathomimetic catecholamines: Synthesis and adrenergic activity of 5,6- and 6,7-dihydroxy-3,4-dihydrospiro[naphthalen-1(2H)-2′,5′- morpholines] 174
Computational Studies on Translocator Protein (TSPO) and its Ligands 174
Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells 174
Novel aminopteroil-sulfonamide derivatives as inhibitors of dihydrofolate reductase and carbonic anhydrase, with potential anti tumor activity 172
Synthesis of sulfonamide-containing N-hydroxyindole-2-carboxylates as inhibitors of human lactate dehydrogenase-isoform 5 172
Structure-Activity Relationship Studies of a New Series of Imidazo2,1-fpurinones as Potent and Selective A3 Adenosine Receptor Antagonists 171
Synthesis and ß-Adrenergic Properties Of (Z)-N-[3-(Alkylamino)-2-hydroxypropilidene](aryl-methyloxy)amines: Effects Of The Configuration Around The Methyloxyiminomethyl(MOIM) Double Bond On The Biopharmacological Properties Of MOIM-type ß-Blocking Agents 169
1-benzilossiimmino-3- ammino-2-propanoli: sintesi e proprietà ß-adrenergiche 167
Analysis of Human Carbonic Anhydrase II: Docking Reliability and Receptor-Based 3D-QSAR Study 167
New Resorcinol-Anandamide "Hybrids" as Potent Cannabinoid Receptor Ligands Endowed with Antinociceptive Activity in Vivo 167
Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models 166
Nuovi agenti ß-bloccanti: Derivati propanolamminici di eteri di ossime completamente alifatiche 165
APPARENT MOLAR SPECIFIC-HEATS OF ORGANIC SOLUTES IN AQUEOUS-SOLUTION 164
Triazole-substituted N-hydroxyindol-2-carboxylates as inhibitors of isoform 5 of human lactate dehydrogenase (hLDH5) 164
Substituted Pyrazolo3,4-bpyridines as Potent A1 Adenosine Antagonists: Synthesis, Biological Evaluation, and Development of an A1 Bovine Receptor Model 163
N-Hydoxyindoles: novel, selective, and efficient inhibitors of isoform 5 of human lactate dehydrogenase (hLDH-5) 162
Pyrazole phenylcyclohexylcarbamates as inhibitors of human fatty acid amide hydrolases (FAAH) 162
The cannabinoid CB2/CB1 selectivity. Homology modelling and automated docking analysis 161
Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: An investigation of the 1,8-naphthyridin-2(1H)-one scaffold 161
Structure-based virtual screening: Identification of novel CB2 receptor ligands 161
Derivatives of 4-Amino-6-hydroxy-2-mercaptopyrimidine as Novel, Potent, and Selective A3 Adenosine Receptor Antagonists 161
MO STUDIES ON THE MECHANISM OF DRUG RECEPTOR INTERACTION .4. INTERACTING CONFORMATIONS OF BETA-ADRENERGIC DRUGS 160
Immune-Modulation and Properties of Absorption and Blood Brain Barrier Permeability of 1,8-Naphthyridine Derivatives. 160
Synthesis and b-blocking activity of (R,S)-(E)-oximeethers of 2,3-dihydro-1,8-naphthyridine and 2,3-dihydrothiopyrano[2,3-b]-pyridine: potential antihypertensive agents. Part IX 159
Totale 20.146
Salva come PNG Salva come JPEG
Categoria #
all - tutte 93.090
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 93.090
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021338 0 0 0 0 0 0 0 0 0 0 0 338
2021/20222.630 59 197 74 185 450 344 78 145 84 75 167 772
2022/20232.902 374 368 191 275 312 430 28 197 494 21 167 45
2023/20242.193 358 262 267 152 333 386 87 43 41 32 39 193
2024/20256.864 38 252 113 385 687 597 562 415 571 831 727 1.686
2025/20266.418 395 962 883 563 523 642 992 365 292 557 196 48
Totale 35.889